Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.37−0.39 (-5.03%)
Close on Nov 16, 2026Market cap $395.25MP/E –Yield –
Avalo Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Avalo Therapeutics's gross margin for the twelve months ending Sep 30, 2023 was 5.5%. For fiscal 2023 it was 33.3%, against 81.0% the year before. The highest annual figure on record is 108.4% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 33.3% | −47.7 |
| FY2022 | Dec 31, 2022 | 81.0% | +8.6 |
| FY2021 | Dec 31, 2021 | 72.4% | −23.1 |
| FY2020 | Dec 31, 2020 | 95.5% | −12.9 |
| FY2019 | Dec 31, 2019 | 108.4% | +54.8 |
| FY2018 | Dec 31, 2018 | 53.6% | −44.1 |
| FY2017 | Dec 31, 2017 | 97.7% | −2.3 |
| FY2016 | Dec 31, 2016 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2024 | Sep 30, 2024 | 386.7% | +355.9 |
| Q3 FY2023 | Sep 30, 2023 | -4.7% | −101.1 |
| Q2 FY2023 | Jun 30, 2023 | -10.1% | +41.6 |
| Q1 FY2023 | Mar 31, 2023 | -16.0% | −54.6 |
| Q4 FY2022 | Dec 31, 2022 | 30.8% | +124.4 |
| Q3 FY2022 | Sep 30, 2022 | 96.5% | +63.7 |
| Q2 FY2022 | Jun 30, 2022 | -51.7% | −149.2 |
| Q1 FY2022 | Mar 31, 2022 | 38.6% | −45.1 |
| Q4 FY2021 | Dec 31, 2021 | -93.6% | −188.3 |
| Q3 FY2021 | Sep 30, 2021 | 32.7% | −60.3 |
| Q2 FY2021 | Jun 30, 2021 | 97.5% | +3.4 |
| Q1 FY2021 | Mar 31, 2021 | 83.7% | −13.9 |
| Q4 FY2020 | Dec 31, 2020 | 94.7% | +0.7 |
| Q3 FY2020 | Sep 30, 2020 | 93.1% | −114.5 |
| Q2 FY2020 | Jun 30, 2020 | 94.2% | +23.4 |
| Q1 FY2020 | Mar 31, 2020 | 97.6% | +39.3 |
| Q3 FY2019 | Sep 30, 2019 | 94.0% | +70.3 |
| Q2 FY2019 | Jun 30, 2019 | 207.5% | +137.3 |
| Q1 FY2019 | Mar 31, 2019 | 70.8% | −9.9 |
| Q4 FY2018 | Dec 31, 2018 | 58.3% | −8.5 |
| Q3 FY2018 | Sep 30, 2018 | 23.6% | −76.4 |
| Q2 FY2018 | Jun 30, 2018 | 70.3% | −29.7 |
| Q1 FY2018 | Mar 31, 2018 | 80.7% | −19.3 |
| Q4 FY2017 | Dec 31, 2017 | 66.7% | – |
| Q3 FY2017 | Sep 30, 2017 | 100.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 100.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 100.0% | – |
See a number that looks wrong?